Association of the -1031T > C polymorphism and soluble TNF-α levels with Acute Coronary Syndrome

Cytokine

Volumn 78, Issue , 2016, Pages 37-43

  Sandoval Pinto, Elena ^a   Padilla Gutiérrez, Jorge Ramón ^a   Valdés Alvarado, Emmanuel ^a   García González, Ilian Janet ^a   Valdez Haro, Angélica ^a   Muñoz Valle, José Francisco ^a   Flores Salinas, Hector Enrique ^b   Brennan Bourdon, Lorena Michele ^a   Valle, Yeminia ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Acute Coronary Syndrome; Genetic polymorphisms; Proinflammatory cytokines; Soluble protein; TNF

Indexed keywords

CYTOSINE; THYMINE; TUMOR NECROSIS FACTOR ALPHA; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; CHI SQUARE TEST; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANK SUM TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TNFA GENE; BLOOD; CASE CONTROL STUDY; DYSLIPIDEMIAS; ETHNOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROMOTER REGION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE CORONARY SYNDROME; AGED; ALLELES; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84947983557     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.11.014     Document Type: Article

References (87)

1. Borrayo-Sánchez G., Madrid-Miller A., Arriaga-Nava R., Ramos-Corrales M.A., García-Aguilar J., Almeida-Gutiérrez E. Risk stratified in the national registry of acute coronary syndromes at the IMSS. Rev. Méd. Inst. Mex Seguro Soc. 2010, 48(3):259-264.
2. Montero Hechavarría E., Rodríguez Leyva B.A., Blanco Gómez L., Vidal Sigas V.M., Mata Mendoza M. Enfoque diagnóstico y terapéutico del síndrome coronario agudo. Medisan 2010, 14(1). 0-0.
3. Escobedo-de la Peña J., Rodríguez-Ábrego G., Buitrón-Granados L.V. Coronary heart disease morbidity and mortality trends at the Instituto Mexicano del Seguro Social. An ecological study of trends. Arch. Cardiol. M. 2010, 80(4):242-248.
4. González Guzmán R., Alcalá Ramírez Enfermedad isquémica del corazón, epidemiología y prevención. Rev. Fac. Med. 2010, 53:35-43.
5. Cannon C.P., Battler A., Brindis R.G., Cox J.L., Ellis S.G., Every N.R., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J. Am. Coll. Cardiol. 2001, 38(7):2114-2130.
6. Nugent R. Chronic diseases in developing countries: health and economic burdens. Ann. N.Y. Acad. Sci. 2008, 1136:70-79.
7. Reichlin T., Twerenbold R., Reiter M., Steuer S., Bassetti S., Balmelli C., et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am. J. Med. 2012, 125(12):1205-1213. e1.
8. Deckers J.W. Classification of myocardial infarction and unstable angina: a re-assessment. Int. J. Cardiol. 2013 Sep, 167(6):2387-2390.
9. López-Bescós L. Introducción. Monocardio 2002, 4(4):167-168.
10. Kumar A., Cannon C.P. Acute coronary syndromes: diagnosis and management, Part I. Mayo Clin. Proc. 2009 Oct, 84(10):917-938.
11. Leiva-Pons J.L. Management of acute coronary syndromes in Mexico: gaps and opportunities to improve outcomes. Am. J. Cardiovasc. Drugs Drugs Dev. Interv. 2009, 9(3):143-148.
12. Solorio S., Hernández-González M.A., Rangel Abundis A., Murillo-Ortiz B. Coronary artery disease in Mexican women. Arch. Cardiol. M. 2007, 77(3):226-231.
13. Cassiani M., Carlos A., Cabrera G. A síndromes coronarios agudos: epidemiología y diagnóstico. Salud Uninorte 2009, 25(1):118-134.
14. Vargas-Alarcón G., Fragoso J.M., Delgadillo H. Acute coronary syndrome. Physiopathology and genetics. Rev. Invest. Clín. Organo Hosp. Enfermedades Nutr. 2011, 63(1):64-74.
15. Babu B.M.V.S., Reddy B.P., Priya V.H.S., Munshi A., Rani H.S., Latha G.S., et al. Cytokine gene polymorphisms in the susceptibility to acute coronary syndrome. Genet. Test Mol. Biomark 2012, 16(5):359-365.
16. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352(16):1685-1695. April 21.
17. Latini R., Bianchi M., Correale E., Dinarello C.A., Fantuzzi G., Fresco C., et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J. Cardiovasc. Pharmacol. 1994, 23(1):1-6.
18. Skoog T., Dichtl W., Boquist S., Skoglund-Andersson C., Karpe F., Tang R., et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart J. 2002 Mar, 23(5):376-383.
19. Jefferis B.J., Whincup P.H., Welsh P., Wannamethee S.G., Rumley A., Lennon L.T., et al. Circulating TNFalpha levels in older men and women do not show independent prospective relations with MI or stroke. Atherosclerosis 2009, 205(1):302-308.
20. Cui G., Wang H., Li R., Zhang L., Li Z., Wang Y., et al. Polymorphism of tumor necrosis factor alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke. J. Neuroinflamm. 2012, 9:235.
21. Schulz R., Aker S., Belosjorow S., Heusch G. TNFalpha in ischemia/reperfusion injury and heart failure. Basic Res. Cardiol. 2004, 99(1):8-11.
22. Schulz R., Heusch G. Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction?. Circulation 2009, 119(10):1355-1357. March 17.
23. Roitenberg G.E., Sharkhun O.O., Ushakova T.I., Serebriakova O.E. Impact of TNF-alpha gene polymorphism, development of atherogenic dyslipidemia and risk of atherosclerosis. Vestn Ross Akad Meditsinskikh Nauk Ross Akad Meditsinskikh Nauk 2010, 3:3-6.
24. Biswas S., Ghoshal P.K., Mandal N. Synergistic effect of anti and pro-inflammatory cytokine genes and their promoter polymorphism with ST-elevation of myocardial infarction. Gene 2014, 544(2):145-151. July 10.
25. Chang W.-T., Wang Y.-C., Chen C.-C., Zhang S.-K., Liu C.-H., Chang F.-H., et al. The -308G/A of tumor necrosis factor (TNF)-α and 825C/T of guanidine nucleotide binding protein 3 (GNB3) are associated with the onset of acute myocardial infarction and obesity in Taiwan. Int. J. Mol. Sci. 2012, 13(2):1846-1857.
26. Hou L., Huang J., Lu X., Wang L., Fan Z., Gu D. Polymorphisms of tumor necrosis factor alpha gene and coronary heart disease in a Chinese Han population: interaction with cigarette smoking. Thromb. Res. 2009, 123(6):822-826.
27. Bennet A.M., van Maarle M.C., Hallqvist J., Morgenstern R., Frostegård J., Wiman B., et al. Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis 2006, 187(2):408-414.
28. Antonicelli R., Olivieri F., Cavallone L., Spazzafumo L., Bonafè M., Marchegiani F., et al. Tumor necrosis factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coron. Artery Dis. 2005, 16(8):489-493.
29. Skoog T., Hamsten A., Eriksson P. Allele-specific chromatin remodeling of the tumor necrosis factor-alpha promoter. Biochem. Biophys. Res. Commun. 2006, 351(3):777-783. December 22.
30. Hohjoh H., Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun. 2001, 2(2):105-109.
31. Cui G., Wang H., Li R., Zhang L., Li Z., Wang Y., et al. Polymorphism of tumor necrosis factor alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and cardiovascular risk factor for ischemic stroke. J. Neuroinflamm. 2012, 9(1):235. October 10.
32. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 1988, 16(3):1215. February 11.
33. INEGI, Instituto Nacional de EstadÍstica y GeografÍa, México DF. Estadísticas a propósito del día Mundial del corazón (revised 18.11.14) . http://www.inegi.org.mx/inegi/contenidos/espanol/prensa/contenidos/estadisticas/2009/corazon09.asp?c=2740%26ep=21.%20n.d.
34. SSA, Secretaria de Salud Publica, México, DF. Guia de Practica Clinica (GPC). Diagnostico y Tratamiento del Infarto Agudo de Miocardio con Elevacion del Segmento ST en Mayoresde 65 años (revised 21.11.14). http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/imss_357_13_iamconelevacionst/imss_357_13_iamconelevacionst_ger.pdf.%20n.d.
35. Schargrodsky H., Hernández-Hernández R., Champagne B.M., Silva H., Vinueza R., Silva Ayçaguer L.C., et al. CARMELA: assessment of cardiovascular risk in seven Latin American cities. Am. J. Med. 2008, 121(1):58-65.
36. Dabek J., Kulach A., Gasior Z. Genetic background of acute coronary syndromes. Eur. J. Int. Med. 2006, 17(3):157-162. May 1.
37. Durán-Varela B.R., Rivera-Chavira B., Franco-Gallegos E. Apego al tratamiento farmacológico en pacientes con diagnóstico de diabetes mellitus tipo 2. Salud Públ. M. 2001, 43(3):233-236.
38. Marín-Reyes F., Rodríguez-Morán M. Apoyo familiar en el apego al tratamiento de la hipertensión arterial esencial. Salud Públ. M. 2001, 43(4):336-339.
39. Sistema de Información en Salud para Población Abierta (SISPA), Dirección General de Epidemiología, Secretaría de Salud, México, 2000.
40. Deedwania P., Kosiborod M., Barrett E., Ceriello A., Isley W., Mazzone T., et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008, 117(12):1610-1619. March 25.
41. Manzanares W., Aramendi I. Hiperglucemia de estrés y su control con insulina en el paciente crítico: evidencia actual. Med. Intensiv. 2010, 34(4):273-281.
42. Fahy B.G., Sheehy A.M., Coursin D.B. Glucose control in the intensive care unit. Crit. Care Med. 2009, 37(5):1769-1776.
43. Sakharova O.V., Inzucchi S.E. Endocrine assessments during critical illness. Crit. Care Clin. 2007, 23(3):467-490.
44. Collier B., Dossett L.A., May A.K., Diaz J.J. Glucose control and the inflammatory response. Nutr. Clin. Pract. Off Publ. Am. Soc. Parenter Enter. Nutr. 2008, 23(1):3-15.
45. Langouche L., Vanhorebeek I., Van den Berghe G. Therapy insight: the effect of tight glycemic control in acute illness. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3(3):270-278.
46. Van den Berghe G., Wouters P.J., Bouillon R., Weekers F., Verwaest C., Schetz M., et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit. Care Med. 2003, 31(2):359-366.
47. Corstjens A.M., van der Horst I.C., Zijlstra J.G., Groeneveld A.J., Zijlstra F., Tulleken J.E., et al. Hyperglycaemia in critically ill patients: marker or mediator of mortality?. Crit. Care 2006, 10(3):216.
48. Finney S.J., Zekveld C., Elia A., Evans T.W. Glucose control and mortality in critically ill patients. JAMA 2003, 290(15):2041-2047.
49. Gabbanelli V., Pantanetti S., Donati A., Principi T., Pelaia P. Correlation between hyperglycemia and mortality in a medical and surgical intensive care unit. Miner. Anestesiol. 2005, 71(11):717-725.
50. Bochicchio G.V., Sung J., Joshi M., Bochicchio K., Johnson S.B., Meyer W., et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J. Trauma 2005, 58(5):921-924.
51. Van den Berghe G., Wouters P., Weekers F., Verwaest C., Bruyninckx F., Schetz M., et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med. 2001, 345(19):1359-1367. November 8.
52. Krinsley J.S. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin. Proc. 2004, 79(8):992-1000.
53. Egi M., Bellomo R., Stachowski E., French C.J., Hart G.K., Hegarty C., et al. Blood glucose concentration and outcome of critical illness: the impact of diabetes. Crit. Care Med. 2008, 36(8):2249-2255.
54. Pittas A.G., Siegel R.D., Lau J. Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials. JPEN J. Parenter. Enteral Nutr. 2006, 30(2):164-172.
55. Devos P., Chioléro R., Van den Berghe G., Preiser J.-C. Glucose, insulin and myocardial ischaemia. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9(2):131-139.
56. Brinkman B.M., Zuijdeest D., Kaijzel E.L., Breedveld F.C., Verweij C.L. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J. Inflamm. 1995 1996, 46(1):32-41.
57. Hohjoh H., Tokunaga K. Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter. Genes Immun. 2001, 2(2):105-109. April 1.
58. Ramírez-Bello J., Vargas-Alarcón G., Tovilla-Zárate C., Fragoso J.M. Single nucleotide polymorphisms (SNPs): functional implications of regulatory-SNP (rSNP) and structural RNA (srSNPs) in complex diseases. Gac Méd. M. 2013, 149(2):220-228.
59. Rubi-Castellanos R., Martínez-Cortés G., Muñoz-Valle J.F., González-Martín A., Cerda-Flores R.M., Anaya-Palafox M., et al. Pre-hispanic Mesoamerican demography approximates the present-day ancestry of mestizos throughout the territory of Mexico. Am. J. Phys. Anthropol. 2009, 139(3):284-294.
60. Liu Y., Jin W., Lu L., Chen Q., Shen W. Association between the -1031T/C polymorphism in tumor necrosis factor-alpha gene and unstable angina. Zhonghua Yi Xue Yi Chuan Xue Za Zhi Zhonghua Yixue Yichuanxue Zazhi Chin. J. Med. Genet. 2009, 26(5):571-574.
61. Asifa G.Z., Liaquat A., Murtaza I., Kazmi S.A.R., Javed Q. Tumor necrosis factor-alpha gene promoter region polymorphism and the risk of coronary heart disease. Sci. World J. 2013, 5(2013):e203492.
62. Monraats P.S., Pires N.M.M., Schepers A., Agema W.R.P., Boesten L.S.M., de Vries M.R., et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J. Off Publ. Fed. Am. Soc. Exp. Biol. 2005, 19(14):1998-2004.
63. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. TEM 2000, 11(8):327-332.
64. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 2000, 21(6):697-738.
65. Vallvé J.-C., Paredes S., Girona J., Uliaque K., Ribalta J., Hurt-Camejo E., et al. Tumor necrosis factor-alpha -1031T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. J. Rheumatol. 2008, 35(9):1697-1703.
66. Jovinge S., Hamsten A., Tornvall P., Proudler A., Båvenholm P., Ericsson C.G., et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47(1):113-118.
67. Popa C., van den Hoogen F.H.J., Radstake T.R.D.J., Netea M.G., Eijsbouts A.E., den Heijer M., et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66(11):1503-1507.
68. Fernández-Real J.M., Gutierrez C., Ricart W., Casamitjana R., Fernández-Castañer M., Vendrell J., et al. The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997, 46(9):1468-1472.
69. Hoffstedt J., Eriksson P., Hellström L., Rössner S., Rydén M., Arner P. Excessive fat accumulation is associated with the TNF alpha-308 G/A promoter polymorphism in women but not in men. Diabetologia 2000, 43(1):117-120.
70. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372(9634):224-233. July 19.
71. Wang Y.-N., Che S.-M., Ma A.-Q. Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha, and IFN-v in acute coronary syndrome. Chin. Med. Sci. J. Chung-Kuo Hsüeh Ko Hsüeh Tsa Chih Chin. Acad. Med. Sci. 2004, 19(2):120-124.
72. Gonzálvez M., Ruiz-Ros J.A., Pérez-Paredes M., Lozano M.L., García-Almagro F.J., Martínez-Corbalán F., et al. Prognostic value of tumor necrosis factor-alpha in patients with ST-segment elevation acute myocardial infarction. Rev. Esp. Cardiol. 2007, 60(12):1233-1241.
73. Search [Internet], (cited 07.10.15). http://e-libraryusa.com/record.php?db=asx%26an=44870564%26highlight=Konrad+Hoetzenecker%26resultId=1%26recordCount=2%26query=Konrad+Hoetzenecker%26fieldcode=AR.
74. Gurrola-Díaz C.M., Sánchez-Enriquez S., Oregon-Romero E., García-López P.M., Garzón de la Mora P., Bastidas-Ramírez B.E., et al. Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome. J. Clin. Lab. Anal. 2009, 23(1):51-56.
75. Deviations in circulating TNFα levels and TNFα production by mononuclear cells in healthy human populations. - PubMed - NCBI [Internet], (cited 15.07.15). http://www.ncbi.nlm.nih.gov.
76. Vázquez-Huerta D.I., Alvarez-Rodríguez B.A., Topete-Reyes J.F., Muñoz-Valle J.F., Parra-Michel R., Fuentes-Ramírez F., et al. Tumor necrosis factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic kidney disease: correlation with clinical variables. Int. J. Clin. Exp. Med. 2014, 7(8):2111-2119.
77. Havlir D.V., Torriani F.J., Schrier R.D., Huang J.Y., Lederman M.M., Chervenak K.A., et al. Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J. Clin. Microbiol. 2001, 39(1):298-303.
78. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., et al. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur. Cytokine Netw. 2006, 17(3):196-201.
79. Cesari M., Penninx B.W.J.H., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and cardiovascular disease (the health, aging and body composition [Health ABC] study). Am. J. Cardiol. 2003, 92(5):522-528. September 1.
80. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res. Rev. 2011, 10(3):319-329.
81. Oregón-Romero E., Vázquez-Del Mercado M., Ruiz-Quezada S.L., Navarro-Hernández R.E., Rangel-Villalobos H., Martínez-Bonilla G., et al. Tumor necrosis factor alpha-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-alpha. J. Invest. Med. Off Publ. Am. Fed. Clin. Res. 2008, 56(7):937-943.
82. Sando I.C., Wang Y., Crisostomo P.R., Markel T.A., Sharma R., Erwin G.S., et al. Females exhibit relative resistance to depressive effects of tumor necrosis factor-alpha on the myocardium. J. Surg. Res. 2008, 150(1):92-99.
83. Wen C.P., Cheng T.Y.D., Tsai S.P., Hsu H.L., Wang S.L. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005, 28(11):2756-2761.
84. Wang M., Crisostomo P., Wairiuko G.M., Meldrum D.R. Estrogen receptor-alpha mediates acute myocardial protection in females. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(6):H2204-H2209.
85. Wang M., Tsai B.M., Reiger K.M., Brown J.W., Meldrum D.R. 17-beta-Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia. J. Mol. Cell Cardiol. 2006, 40(2):205-212.
86. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308(5728):1583-1587. June 10.
87. Sohail M., Kaul A., Bali P., Raziuddin M., Singh M.P., Singh O.P., et al. Alleles -308A and -1031C in the TNF-alpha gene promoter do not increase the risk but associated with circulating levels of TNF-alpha and clinical features of vivax malaria in Indian patients. Mol. Immunol. 2008, 45(6):1682-1692.